SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:gup.ub.gu.se/299424"
 

Search: onr:"swepub:oai:gup.ub.gu.se/299424" > Value of flow cytom...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Value of flow cytometry for MRD-based relapse prediction in B-cell precursor ALL in a multicenter setting.

Modvig, S (author)
Copenhagen University Hospital,Vilnius University,Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.,Vilnius Univ Hosp, Santaros Klin, Hematol Oncol & Transfus Med Ctr, Vilnius, Lithuania.
Hallböök, Helene (author)
Uppsala universitet,Uppsala University,Copenhagen University Hospital,Oslo university hospital,Hematologi,Copenhagen Univ Hosp, Rigshosp, Dept Clin Immunol, Copenhagen, Denmark.,Oslo Univ Hosp, Dept Pathol, Lab Mol Pathol, Oslo, Norway.
Madsen, H O (author)
Umeå University,Umeå Univ, Dept Med Biosci, Pathol, Umeå, Sweden.
show more...
Siitonen, S (author)
University of Helsinki,University of Copenhagen,Univ Helsinki, Clin Chem, Helsinki, Finland.;Helsinki Univ Hosp, Helsinki, Finland.,Univ Copenhagen, Sect Biostat, Copenhagen, Denmark.
Rosthøj, S (author)
Tierens, A (author)
University of Toronto,Oslo university hospital,Univ Hlth Network, Lab Med Program, Toronto, ON, Canada.;Univ Toronto, Toronto, ON, Canada.;Univ Hosp Oslo, Dept Pathol, Oslo, Norway.
Juvonen, V (author)
University of Turku,Univ Turku, Dept Clin Chem, Turku, Finland.;Univ Turku, Lab Div, Turku, Finland.;Turku Univ Hosp, Turku, Finland.
Osnes, L T N (author)
Oslo university hospital,Herlev Hospital,Oslo Univ Hosp, Dept Immunol, Oslo, Norway.,Herlev Univ Hosp, Dept Hematol, Herlev, Denmark.
Vålerhaugen, H (author)
Hultdin, Magnus (author)
Umeå universitet,Patologi
Matuzeviciene, R (author)
Vilnius University,Vilnius Univ, Inst Biomed Sci, Fac Med, Dept Physiol Biochem Microbiol & Lab Med, Vilnius, Lithuania.;Vilnius Univ Hosp, Santaros Klin, Ctr Lab Med, Vilnius, Lithuania.
Stoskus, M (author)
Ehinger, M. (author)
Lund University,Lunds universitet,Uppsala University,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital,Skane Univ Hosp, Dept Clin Genet & Pathol, Lund, Sweden.;Lund Univ, Dept Clin Sci Oncol & Pathol, Lund, Sweden.
Lilleorg, A (author)
North Estonia Medical Centre,North Estonia Med Ctr, Dept Clin Immunol, Tallinn, Estonia.
Ehinger, M (author)
Norén-Nyström, Ulrika (author)
Umeå University,Umeå universitet,Pediatrik,Umeå Univ, Dept Clin Sci, Pediat, Umeå, Sweden.
Toft, N (author)
Taskinen, M (author)
Helsinki University Central Hospital,Helsinki Univ Hosp, Div Pediat Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland.
Jónsson, O G (author)
National University Hospital of Iceland,Landspitali Univ Hosp, Childrens Hosp, Reykjavik, Iceland.
Pruunsild, K (author)
Tallinn Children's Hospital,Tallinn Childrens Hosp, Tallinn, Estonia.
Vaitkeviciene, G (author)
Vilnius University,Vilnius Univ Hosp, Santariskiu Klin, Childrens Hosp, Vilnius, Lithuania.
Vettenranta, K (author)
University of Helsinki,Univ Helsinki, Helsinki, Finland.;Univ Helsinki, Childrens Hosp, Helsinki, Finland.
Lund, B (author)
St. Olav’s University Hospital,St Olavs Univ Hosp, Dept Pediat, Trondheim, Norway.;NTNU, Dept Clin & Mol Med, Trondheim, Norway.
Abrahamsson, Jonas, 1954 (author)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för pediatrik,Institute of Clinical Sciences, Department of Pediatrics,Sahlgrenska University Hospital,Sahlgrens Univ Hosp, Inst Clin Sci, Dept Pediat, Gothenburg, Sweden.
Porwit, A. (author)
Lund University,Lunds universitet,Patologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pathology, Lund,Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund Univ, Fac Med, Dept Clin Sci, Div Oncol & Pathol, Lund, Sweden.
Schmiegelow, K (author)
Copenhagen University Hospital,Copenhagen Univ Hosp, Rigshosp, Dept Pediat & Adolescent Med, Copenhagen, Denmark.;Univ Copenhagen, Inst Clin Med, Fac Med, Copenhagen, Denmark.
Marquart, H V (author)
Marincevic, Millaray, 1983- (author)
Uppsala universitet,Klinisk och experimentell patologi
show less...
 (creator_code:org_t)
2020-12-14
2021
English.
In: Leukemia. - : Springer Science and Business Media LLC. - 1476-5551 .- 0887-6924. ; 35, s. 1894-1906
Related links:
https://www.nature.c...
show more...
https://doi.org/10.1...
https://umu.diva-por... (primary) (Raw object)
http://dx.doi.org/10... (free)
https://uu.diva-port... (primary) (Raw object)
https://gup.ub.gu.se...
https://doi.org/10.1...
https://urn.kb.se/re...
https://lup.lub.lu.s...
https://urn.kb.se/re...
show less...
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • PCR of TCR/Ig gene rearrangements is considered the method of choice for minimal residual disease (MRD) quantification in BCP-ALL, but flow cytometry analysis of leukemia-associated immunophenotypes (FCM-MRD) is faster and biologically more informative. FCM-MRD performed in 18 laboratories across seven countries was used for risk stratification of 1487 patients with BCP-ALL enrolled in the NOPHO ALL2008 protocol. When no informative FCM-marker was available, risk stratification was based on real-time quantitative PCR. An informative FCM-marker was found in 96.2% and only two patients (0.14%) had non-informative FCM and non-informative PCR-markers. The overall 5-year event-free survival was 86.1% with a cumulative incidence of relapse (CIR5y) of 9.5%. FCM-MRD levels on days 15 (HzR 4.0, p<0.0001), 29 (HzR 2.7, p<0.0001), and 79 (HzR 3.5, p<0.0001) associated with hazard of relapse adjusted for age, cytogenetics, and WBC. The early (day 15) response associated with CIR5y adjusted for day 29 FCM-MRD, with higher levels in adults (median 2.4×10-2 versus 5.2×10-3, p<0.0001). Undetectable FCM- and/or PCR-MRD on day 29 identified patients with a very good outcome (CIR5y=3.2%). For patients who did not undergo transplantation, day 79 FCM-MRD>10-4 associated with a CIR5y=22.1%. In conclusion, FCM-MRD performed in a multicenter setting is a clinically useful method for MRD-based treatment stratification in BCP-ALL.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Pediatrik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Pediatrics (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • Leukemia (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view